Publish in this journal
Journal Information
Vol. 69. Issue 12.
Pages 1215 (December 2016)
Vol. 69. Issue 12.
Pages 1215 (December 2016)
Image in cardiology
Full text access
Cardiac Amyloidosis Detected Using 18F-florbetapir PET/CT
Amiloidosis cardiaca detectada mediante PET/TC con 18F-florbetapir
Pilar García-Gonzáleza,
Corresponding author
, María del Puig Cozar-Santiagob, Alicia M. Maceirac
a Unidad de Imagen Cardiaca-ERESA, Consorcio Hospital General Universitario de Valencia, Valencia, Spain
b Servicio de Medicina Nuclear, ERESA, Consorcio Hospital General Universitario de Valencia, Valencia, Spain
c Unidad de Imagen Cardiaca-ERESA, Hospital Arnau de Vilanova, Valencia, Spain
Related content
Rev Esp Cardiol. 2017;70:616-710.1016/j.rec.2017.02.040
Javier Segovia Cubero, Rocío Segovia Moreno
This item has received
Article information
Full Text
Download PDF
Figures (2)
Additional material (2)
Full Text

Cardiac amyloidosis (CA) is caused by amyloid deposits in the heart and is usually secondary to systemic amyloidosis. Echocardiography and cardiac magnetic resonance imaging are useful for the diagnosis of CA but they do not specifically distinguish it from other infiltrative heart diseases.

Positron emission tomography/computed tomography (PET/CT) with 18F-florbetair is an accurate nuclear medicine imaging tool for the detection of cerebral amyloid and diagnosis of Alzheimer disease and is currently a promising imaging modality for the detection of CA and extracardiac amyloidosis.

We present the case of a 75-year-old man with a history of multiple myeloma and progressive heart failure symptoms. Echocardiography showed left ventricular hypertrophy while cardiac magnetic resonance imaging, to rule out infiltrative disease, revealed mild left ventricular dysfunction (videos 1 and 2 of the supplementary material), altered gadolinium kinetics, and the presence of global subendocardial late enhancement in the left ventricle and atrium (Figure 1), suggestive of CA.

Figure 1

Axial images and 3-dimensional cardiac reconstruction with 18F-florbetapir PET/CT 40minutes after intravenous administration of 381 MBq revealed an intense and heterogeneous uptake of the amyloid tracer (Figure 2), confirming the diagnosis of CA.

Figure 2

Imaging with 18F-florbetapir PET/CT permits the early and noninvasive detection of cardiac amyloid, precluding the need for myocardial biopsy. In addition, because this modality avoids the risk of complications associated with invasive procedures, it is more cost-effective than cardiac biopsy for the diagnosis of CA.


This work was supported by a grant from the 2014 Program of ERESA Funding Group to Mariano Linares.

Copyright © 2016. Sociedad Española de Cardiología
Revista Española de Cardiología (English Edition)

Subscribe to our newsletter

View newsletter history
Article options
Supplemental materials
es en

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?